Project Mosaic
Project Mosaic is a collaborative research initiative and consortium of ALS nonprofits and industry stakeholders focused on accelerating drug development for Amyotrophic Lateral Sclerosis (ALS), particularly the sporadic form which represents over 90% of cases and is highly heterogeneous. The project develops and validates standardized, commercially scalable cell-based disease models derived from patient iPSCs that recapitulate key ALS pathology such as TDP-43 dysfunction. These models enable precision medicine approaches by allowing drug developers to test candidate therapies on diverse patient-derived lines, improving clinical trial success rates. The initiative also plans to develop an AI-based drug testing platform to predict drug efficacy and identify biomarkers for patient stratification. Supported by leading ALS nonprofits and scientific advisors, Project Mosaic aims to transform ALS drug development by providing better tools for researchers and enabling personalized treatments, with potential impact on other neurodegenerative diseases. The project is currently raising funds to advance model industrialization, commercialization, and platform development, targeting a $9-10M budget over three years.
Project Mosaic
Project Mosaic is a collaborative research initiative and consortium of ALS nonprofits and industry stakeholders focused on accelerating drug development for Amyotrophic Lateral Sclerosis (ALS), particularly the sporadic form which represents over 90% of cases and is highly heterogeneous. The project develops and validates standardized, commercially scalable cell-based disease models derived from patient iPSCs that recapitulate key ALS pathology such as TDP-43 dysfunction. These models enable precision medicine approaches by allowing drug developers to test candidate therapies on diverse patient-derived lines, improving clinical trial success rates. The initiative also plans to develop an AI-based drug testing platform to predict drug efficacy and identify biomarkers for patient stratification. Supported by leading ALS nonprofits and scientific advisors, Project Mosaic aims to transform ALS drug development by providing better tools for researchers and enabling personalized treatments, with potential impact on other neurodegenerative diseases. The project is currently raising funds to advance model industrialization, commercialization, and platform development, targeting a $9-10M budget over three years.